Clik here to view.
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize...
WALTHAM, Mass. ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced it has entered into an exclusive...
View ArticleClik here to view.
InnoCare Releases 2023 Interim Results and Business Highlights
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023. Financial...
View ArticleClik here to view.
The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan...
FLORENCE, Italy & NEW YORK The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned...
View ArticleClik here to view.
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as...
PALO ALTO, Calif. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360®...
View ArticleClik here to view.
LabGenomics USA LLC acquires QDx Pathology in a Strategic Move to Expand its...
ROCKVILLE, Md. LabGenomics USA, a subsidiary of LabGenomics Co., Ltd., announced its acquisition of QDx Pathology, a leader in molecular and diagnostic pathology. The acquisition is expected to have...
View ArticleClik here to view.
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody...
View ArticleClik here to view.
百奥赛图与Myricx达成抗体评估、选择与授权协议，用于ADC药物开发
中国北京 (美国商业资讯)– 百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK），一家创新技术驱动新药研发的国际性生物技术公司宣布与Myricx Bio（“Myricx”），一家专注于发现和开发用于ADC的全新选择性细胞毒载荷的英国生物技术公司达成抗体评估、选择与授权协议。...
View ArticleClik here to view.
DS-3939 Enters Clinical Development in Patients Across Several Types of...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS-3939 in patients with several types...
View ArticleClik here to view.
バイオサイトジェン、MyricxとADC開発のための抗体評価、オプションおよびライセンス契約を締結
北京 （ビジネスワイヤ） — 新型抗体治療薬の発見に注力する世界的なバイオテクノロジー企業であるバイオサイトジェン（HKEX：02315）は、Myricx...
View ArticleClik here to view.
Monrol宣布投资扩大其n.c.a. 镥-177产能
伊斯坦布尔 (美国商业资讯)– 世界领先的放射性药物生产商之一Eczacıbaşı Monrol Nuclear Products Co.（Monrol）决定投资3500万欧元，用于提高其非载体添加型镥-177（n.c.a. Lu-177）的产能，以满足全球对该产品日益增长的需求。 Monrol在其生产设施中制造符合高质量标准的放射性药物，计划通过扩建土耳其Monrol...
View ArticleClik here to view.
モンロール、無担体ルテチウム-177の生産能力拡大に向けた投資を発表
イスタンブール （ビジネスワイヤ） — エジザージュバシュ・モンロール・ニュークリア・プロダクツ（モンロール）、世界をリードする放射性医薬品企業のひとつである当社は、3,500万ユーロを投資して無担体ルテチウム-177（n.c.a. Lu-177）の生産能力を増加し、世界的な需要に対応することを決定しました。...
View ArticleClik here to view.
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic...
CAMBRIDGE, Mass. & SHANGHAI, China 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative...
View ArticleClik here to view.
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for...
View ArticleClik here to view.
RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or...
CAMBRIDGE, Mass. RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, was part of a collaboration that recently shared...
View ArticleClik here to view.
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the...
View ArticleClik here to view.
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material...
SEATTLE AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a Lentiviral vector (LVV) expansion to its AGCellerate program...
View ArticleClik here to view.
PharmaEssentia and MPN Advocacy ＆ Education International Launch New...
BURLINGTON, Mass. & EAST LANSING, Mich. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging...
View ArticleClik here to view.
AGCバイオロジクス、9か月以内に1e11 TU以上のLVV材料を提供することを保証
シアトル （ビジネスワイヤ） — 世界大手のバイオ医薬品開発製造受託機関（CDMO）であるAGCバイオロジクスは、製造管理及び品質管理に関する基準（GMP）に準拠した臨床試験用の材料を迅速に提供するように設計されたAGCellerateプログラムを拡張し、レンチウイルスベクター（LVV）を組み入れると発表しました。AGCellerate...
View ArticleClik here to view.
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2...
TOKYO & MUNICH ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced non-small cell...
View ArticleClik here to view.
PharmaEssentia Included in FTSE Russell Indices
TAIPEI PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology...
View Article